Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies

Digestive Diseases

Volumn 32, Issue 5, 2014, Pages 631-636

  Trauner, Michael ^a   Halilbasic, Emina ^a   Kazemi Shirazi, Lili ^a   Kienbacher, Christian ^a   Staufer, Katharina ^a   Traussnigg, Stefan ^a   Hofer, Harald ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

24 norUrsodeoxycholic acid; Bile acids; Fibrosing cholangiopathies; Nuclear receptor agonists; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

BILE ACID; CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PREGNANE X RECEPTOR; SIMTUZUMAB; URSODEOXYCHOLIC ACID; VITAMIN D RECEPTOR; 24-NORURSODEOXYCHOLIC ACID; CELL RECEPTOR; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ARTICLE; BILE DUCT DISEASE; END STAGE LIVER DISEASE; FIBROSING CHOLANGIOPATHY; HUMAN; INFLAMMATORY BOWEL DISEASE; LIVER TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; AGONISTS; ANALOGS AND DERIVATIVES; CHOLANGITIS, SCLEROSING; METABOLISM; CLINICAL FEATURE; CLINICAL PRACTICE; CONFERENCE PAPER; DISEASE COURSE; EXTRACELLULAR MATRIX; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; SURVIVAL;

BILE ACIDS AND SALTS; CHOLANGITIS, SCLEROSING; HUMANS; LIGANDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; URSODEOXYCHOLIC ACID;

EID: 84904653912     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000360517     Document Type: Article

References (48)

1. Maillette de Buy Wenniger LJ, Oude Elferink RP, Beuers U: Molecular targets for the treatment of fibrosing cholangiopathies. Clin Pharmacol Ther 2012; 92: 381-387.
2. Hirschfield GM, Heathcote EJ, Gershwin ME: Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010; 139: 1481-1496.
3. Hirschfield GM, Gershwin ME: The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 2013; 8: 303-330.
4. Pollheimer MJ, Halilbasic E, Fickert P, Trauner M: Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011; 25: 727-739.
5. Krones E, Graziadei I, Trauner M, Fickert P: Evolving concepts in primary sclerosing cholangitis. Liver Int 2012; 32: 352-569.
6. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD: Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013; 145: 521-536.
7. Hirschfield GM, Karlsen TH, Lindor KD, Adams DH: Primary sclerosing cholangitis. Lancet 2013; 382: 1587-1599.
8. Karlsen TH, Boberg KM: Update on primary sclerosing cholangitis. J Hepatol 2013; 59: 571-582.
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
10. Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ; American Association for the Study of Liver Diseases: Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-678.
11. Trauner M, Halilbasic E: Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140: 1120- 1125.
12. Halilbasic E, Claudel T, Trauner M: Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol 2013; 58: 155-168.
13. Halilbasic E, Baghdasaryan A, Trauner M: Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis 2013; 17: 161-189.
14. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA, Naber AH, Kingma PJ, van Buuren HR, van Hoek B, Vleggaar FP, van Geloven N, Beuers U, Ponsioen CY; Epi- PSCPBC Study Group: Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-2055.
15. Cullen SN, Chapman RW: The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006; 26: 52-61.
16. Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP: The challenges in primary sclerosing cholangitis - aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008; 48(suppl 1):S38-S57.
17. Paumgartner G, Beuers U: Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis 2004; 8: 67-81, vi.
18. Pusl T, Beuers U: Ursodeoxycholic acid treatment of vanishing bile duct syndromes. World J Gastroenterol 2006; 12: 3487-3495.
19. Beuers U: Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318-328.
20. Hohenester S, Oude-Elferink RP, Beuers U: Primary biliary cirrhosis. Semin Immunopathol 2009; 31: 283-307.
21. Wiencke K, Boberg KM: Current consensus on the management of primary sclerosing cholangitis. Clin Res Hepatol Gastroenterol 2011; 35: 786-791.
22. Trauner M, Halilbasic E, Baghdasaryan A, Moustafa T, Krones E, Fickert P, Hofer H, Penner E: Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment. Dig Dis 2012; 30(suppl 1):39-47.
23. Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S, Theilmann L: Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol 1997; 26: 560-566.
24. Schteingart CD, Hagey LR, Setchell KD, Hofmann AF: 5?-Hydroxylation by the liver. Identification of 3,5,7-trihydroxy nor -bile acids as new major biotransformation products of 3,7-dihydroxy nor -bile acids in rodents. J Biol Chem 1993; 268: 11239-11246.
25. Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, Steinbach JH, Schteingart CD, Olinga P, Groothuis GM: Novel biotransformation and physiological properties of nor ursodeoxycholic acid in humans. Hepatology 2005; 42: 1391-1398.
26. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M: 24- nor Ursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-481.
27. Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M: Side chain structure determines unique physiologic and therapeutic properties of nor ursodeoxycholic acid in Mdr2-/- mice. Hepatology 2009; 49: 1972- 1981.
28. Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, Kratky D, Sattler W, Reicher H, Sinner F, Gumhold J, Silbert D, Fauler G, Hofler G, Lass A, Zechner R, Trauner M: Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology 2012; 142: 140-151.
29. Fickert P, Pollheimer MJ, Silbert D, Moustafa T, Halilbasic E, Krones E, Durchschein F, Thuringer A, Zollner G, Denk H, Trauner M: Differential effects of nor UDCA and UDCA in obstructive cholestasis in mice. J Hepatol 2013; 58: 1201-1208.
30. Beuers U, Hohenester S, de Buy Wenniger LJ, Kremer AE, Jansen PL, Elferink RP: The biliary HCO 3 - umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010; 52: 1489-1496.
31. Beuers U, Maroni L, Elferink RO: The biliary HCO 3 - umbrella: experimental evidence revisited. Curr Opin Gastroenterol 2012; 28: 253-257.
32. Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, Trauner M: Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002; 123: 1238-1251.
33. Trauner M, Halilbasic E: Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140: 1120- 1125.
34. Schaap FG, Trauner M, Jansen PL: Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11: 55- 67.
35. Hov JR, Keitel V, Laerdahl JK, Spomer L, Ellinghaus E, El Sharawy A, Melum E, Boberg KM, Manke T, Balschun T, Schramm C, Bergquist A, Weismuller T, Gotthardt D, Rust C, Henckaerts L, Onnie CM, Weersma RK, Sterneck M, Teufel A, Runz H, Stiehl A, Ponsioen CY, Wijmenga C, Vatn MH; IBSEN Study Group, Stokkers PC, Vermeire S, Mathew CG, Lie BA, Beuers U, Manns MP, Schreiber S, Schrumpf E, Haussinger D, Franke A, Karlsen TH: Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One 2010; 5: e12403.
36. Hov JR, Keitel V, Schrumpf E, Haussinger D, Karlsen TH: TGR5 sequence variation in primary sclerosing cholangitis. Dig Dis 2011; 29: 78-84.
37. Nijmeijer RM, Gadaleta RM, van Mil SW, van Bodegraven AA, Crusius JB, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, Verspaget HW, Weersma RK, van der Woude CJ, Stapelbroek JM, Schipper ME, Wijmenga C, van Erpecum KJ, Oldenburg B; Dutch Initiative on Crohn, Colitis (ICC): Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS One 2011; 6:e23745.
38. Stojancevic M, Stankov K, Mikov M: The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Can J Gastroenterol 2012; 26: 631- 637.
39. Attinkara R, Mwinyi J, Truninger K, Regula J, Gaj P, Rogler G, Kullak-Ublick GA, Eloranta JJ; Swiss IBD Cohort Study Group: Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Res Notes 2012; 5: 461.
40. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW: Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011; 60: 463-472.
41. Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M: Dual farnesoid X receptor/ TGR5 agonist INT-767 reduces liver injury in the Mdr2-/-(Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO 3 - output. Hepatology 2011; 54: 1303- 1312.
42. Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, Stoger U, Arrese M, Pizarro M, Solis N, Carrasco G, Caligiuri A, Sombetzki M, Reisinger E, Tsybrovskyy O, Zatloukal K, Denk H, Jaeschke H, Pinzani M, Trauner M: Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 2009; 175: 2392-2405.
43. Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A: Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology 2012; 142: 355-365.
44. Baghdasaryan A, Chiba P, Trauner M: Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med 2013, Epub ahead of print.
45. Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K: Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol 2010; 45: 758-762.
46. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thuringer A, Leski K, Fickert P, Karpen SJ, Trauner M: Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010; 59: 521-530.
47. Hochrath K, Ehnert S, Ackert-Bicknell CL, Lau Y, Schmid A, Krawczyk M, Hengstler JG, Dunn J, Hiththetiya K, Rathkolb B, Micklich K, Hans W, Fuchs H, Gailus-Durner V, Wolf E, de Angelis MH, Dooley S, Paigen B, Wildemann B, Lammert F, Nussler AK: Modeling hepatic osteodystrophy in Abcb4-deficient mice. Bone 2013; 55: 501-511.
48. He H, Mennone A, Boyer JL, Cai SY: Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011; 53: 548-557.